ScienceExplain

Why the Same Drug Works Differently Between People

Advanced

1. Quick Summary

The same dose of the same drug produces different blood concentrations and different effects in different people. Weight, age, kidney and liver function, genetics, diet and concurrent medications all contribute.

Why the Same Drug Works Differently Between People
A network: connected nodes passing things along.

Metabolism is often the dominant factor. Many drugs are cleared by a small number of liver enzyme families, and common genetic variants make some people fast metabolisers and others slow ones, changing exposure substantially for the same dose.

For drugs with a narrow margin between effective and toxic concentrations, this variation has clinical consequences: standard doses under-treat some patients and harm others.

Pharmacogenomics aims to genotype the relevant enzymes in advance and adjust dosing or drug choice accordingly. Adoption has been real but uneven, concentrated where the evidence is strongest.

2. What It Means

A prodrug is an important special case. Some medications are inactive until the body converts them, so a fast metaboliser gets more active drug and a slow metaboliser gets little effect — the opposite of the usual pattern.

Exposure is what matters. Plasma concentration over time integrates absorption, distribution, metabolism and excretion, and it is exposure rather than dose that determines both effect and toxicity.

3. Why It Happens

Drug-drug interactions are the most common avoidable source of variation. One medication inhibiting the enzyme that clears another can raise exposure dramatically, and this is predictable in principle but frequently missed in practice.

Transporter proteins matter as much as enzymes. Uptake and efflux transporters control whether a drug reaches its site of action or is pumped back out, and variation in them affects response independently of metabolism.

Genetic effect sizes vary by ancestry, and most reference data has historically come from populations of European descent. This is a recognised equity problem: applying these tools broadly requires data from the populations being treated.

Evidence standards are the bottleneck. Genotyping is cheap; demonstrating that acting on the result improves outcomes requires trials, and those exist for only a subset of gene-drug pairs.

4. Real Examples

Clotting-related drugs: among the clearest cases, where metaboliser status materially changes dose requirements and bleeding risk.

Certain cancer therapies: dosing or eligibility tied to specific metabolic or tumour genetic markers, where testing is already standard.

Psychiatric medications: plausible and clinically interesting, with more variable evidence and ongoing debate about routine testing.

Preemptive panel testing: genotyping once and storing results in the medical record so the information is available whenever a relevant drug is prescribed.

5. How It Affects Us

For patients on narrow-therapeutic-range drugs, asking whether genetic testing is recommended for that specific medication is reasonable.

Preventing interactions is more impactful than most genetic testing: an up-to-date medication list, including over-the-counter drugs and supplements, is the single most useful thing.

Kidney and liver function change with age and illness, so dosing needs revisiting over time rather than set once.

For health systems, preemptive testing is attractive in principle but depends on results being actually used at the point of prescribing.

6. Key Takeaways

  • Metabolising enzyme variants make people fast or slow processors of the same drug, changing exposure substantially.
  • For prodrugs the direction reverses — fast metabolisers get more active drug.
  • Drug-drug interactions are the most common and most preventable source of unexpected exposure.
  • Reference genetic data is uneven across populations, which limits fair application.
  • Testing is cheap; evidence that acting on results improves outcomes exists for only some gene-drug pairs.